Accretion Pharmaceuticals Quarterly Results for Trading Insights
In 2026, Accretion Pharmaceuticals (ACCPL) reported revenue ₹0 Cr and net profit ₹0 Cr. Also explore Accretion Pharmaceuticals share price performance to track price trends across different timeframes.
ACCPL Quarterly Results — Revenue, Profit & EPS Highlights
Accretion Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with Accretion Pharmaceuticals valuation methods to assess whether the stock is under or overvalued.
- Revenue of ₹58 Cr in March 2025 (+0.0% vs March 2025, +346.2% vs March 2024)
- Net Profit of ₹7 Cr in March 2025 (+0.0% vs March 2025, +250.0% vs March 2024)
- EBITDA of ₹12 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 21.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹8.48 in March 2025 (+0.0% vs March 2025)
Accretion Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ACCPL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 0 | 58 | 13 | - | - |
| Net Profit (₹ Cr) | 0 | 7 | 2 | - | - |
| EBITDA (₹ Cr) | 0 | 12 | 3 | - | - |
| EPS (₹) | 0.00 | 8.48 | 1.96 | - | - |
| Operating Margin (%) | 0.0% | 21.0% | 19.0% | - | - |
ACCPL Share Price Trend — 1-Year Movement Across Quarterly Results
Accretion Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Accretion Pharmaceuticals stock price NSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ACCPL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Accretion Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹437,014.87 Cr | 1847.9 | 14,875 | 3,125 | +10.8% | - | 21.0% | 142.1 |
|
Divis Laboratories
Sept 2025 |
₹175,726.93 Cr | 6710.5 | 2,860 | 689 | +7.1% | - | 24.1% | 258.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹147,504.68 Cr | 4380.8 | 3,219 | 591 | +11.3% | - | 18.4% | 249.8 |
|
Lupin
Sept 2025 |
₹111,651.09 Cr | 2379.5 | 6,921 | 1,485 | +23.2% | - | 21.5% | 73.5 |
|
Cipla
Sept 2025 |
₹110,213.60 Cr | 1347.0 | 7,716 | 1,353 | +12.0% | - | 17.5% | 80.5 |
All amounts in ₹ Crores